Clinical trials
Lung Cancer, Small Cell clinical trials
Below are recruiting lung cancer, small cell clinical trials, each written for real people, not researchers. We’re tracking 1,516 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05257967Recruiting
Testing spinal fluid in EGFR-mutant lung cancer with brain covering spread
This trial looks at spinal fluid (also called CSF) in adults with EGFR-mutant lung cancer that has spread to the lining around the brain/spinal cord. The goal is to better understand the disease and what the spinal fluid tests may show to guide care.
Vancouver, British ColumbiaAges 18 years+ - NCT05265429Recruiting
Study of young people’s lung cancer biology
This study looks at biological samples from people diagnosed with lung cancer at age 45 or younger. It may help researchers understand how young lung cancers differ, which could guide future treatments.
Boston, MassachusettsAges 15 years+ - NCT05269381RecruitingPhase 1/Phase 2
Personalized cancer vaccine with pembrolizumab for advanced tumors
This study makes a custom vaccine from your tumor’s genetic information and gives it with pembrolizumab (an immune therapy). It aims to help control advanced solid tumors by teaching your immune system to recognize cancer-specific targets.
Jacksonville, FloridaAges 16 years+ - NCT05269485RecruitingPhase 1/Phase 2
Hypofractionated radiation for stage III lung cancer
This trial studies a radiation treatment schedule called “hypofractionated radiotherapy” for people with locally advanced (stage III) non-small cell lung cancer who cannot have surgery. It aims to see whether this radiation approach works well and is tolerable for your cancer stage.
Hefei, AnhuiAges 18–70 - NCT05271292RecruitingPhase 1/Phase 2
Chiauranib for advanced cancers that returned or won’t respond
This Phase 1/2 study tests chiauranib in people with advanced solid cancers (including small cell lung cancer) that have come back or no longer respond to standard treatments. It aims to find a safe dose and see whether the treatment can help shrink tumors.
Encinitas, CaliforniaAges 18 years+ - NCT05271916RecruitingPhase 1/Phase 2
New targeted drugs for advanced lung cancer with EGFR L858R
This study tests whether taking dacomitinib plus anlotinib as a first treatment can shrink or control advanced lung cancer that has the EGFR L858R mutation. It may help people who have not had any standard drug treatment yet, especially if their brain metastases are stable.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05278052RecruitingPhase 3
Maintenance therapy alone versus radiation plus maintenance for lung cancer
This trial compares standard maintenance treatment versus adding focused radiation to remaining limited (oligometastatic) spots in the body after initial chemotherapy. It aims to see whether treating those limited spots with radiation can improve outcomes without unacceptable side effects.
Mumbai, MaharashtraAges 18–99 - NCT05276726RecruitingPhase 1/Phase 2
Test drug JAB-21822 for KRAS G12C NSCLC with STK11
This trial studies how well the drug JAB-21822 works in people with advanced or spread lung cancer (NSCLC) that has a specific genetic change: KRAS G12C, plus STK11 and no KEAP1 change. It’s designed to see safety and early signs of effectiveness, especially if you haven’t been treated much yet.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05277844RecruitingPhase 2
Radiation plus targeted pill vs pill alone for EGFR/ALK-NSCLC
This study tests whether adding focused radiation to a targeted cancer pill works better than the pill by itself. It is for people with advanced non-small cell lung cancer (NSCLC) whose tumor has an EGFR or ALK/ROS driver mutation and who have not gotten worse after starting the targeted pill.
Mumbai, MaharashtraAges 18–99 - NCT05283330RecruitingPhase 1
Tested 212Pb imaging drug for certain advanced GRPR tumors
This early-phase study tests how safe and tolerable an experimental radiation drug is for adults with certain advanced or metastatic cancers that show a target called GRPR. Doctors will also use special scans to confirm the tumor has the target so the treatment can be delivered to the right place.
Chicago, IllinoisAges 18 years+ - NCT05284539RecruitingPhase 2
Chemo plus immunotherapy for mutated advanced lung cancer
This trial studies whether combining platinum chemotherapy with immune “checkpoint” medicine works better for people with stage IV lung cancer that has EGFR, ALK, or ROS1 mutations. It focuses on tumors that have grown again after first-line treatment.
Changsha, HunanAges 18 years+ - NCT05288205RecruitingPhase 1/Phase 2
JAB-21822 plus JAB-3312 for KRAS G12C solid tumors
This Phase 1/2a trial tests two investigational pills (JAB-21822 and JAB-3312) in people with advanced solid cancers that have a KRAS G12C mutation. It’s for cases where standard treatments have failed or aren’t suitable, to see if the drugs can shrink tumors and improve outcomes.
Hefei, AnhuiAges 18 years+ - NCT05292521Recruiting
Quality-of-life program to help early lung cancer decisions
This trial tests a quality-of-life support program meant to help people with early-stage lung cancer think through their treatment choices. It may help you feel more informed and more confident about deciding between treatments like surgery and SBRT.
Buffalo, New YorkAges 18 years+ - NCT05295212RecruitingPhase 2
Atezolizumab plus chemo before surgery for lung cancer
This trial studies whether adding atezolizumab (an immune medicine) to standard platinum-based chemotherapy before surgery can improve outcomes for operable stage II–IIIB non-small cell lung cancer. The goal is to shrink the tumor and increase the chance the cancer can be removed with better results.
Changsha, HunanAges 18 years+ - NCT05296564RecruitingPhase 1/Phase 2
TCR cell therapy for NY-ESO-1 positive metastatic cancers
This study tests a customized immune-cell treatment made from your own T cells to attack cancers that have NY-ESO-1. It may help shrink tumors in people with metastatic or hard-to-treat cancer when other treatments have not worked.
JerusalemAges 18–70 - NCT05334277RecruitingPhase 2
Test furmonertinib for advanced EGFR-mutant lung cancer
This Phase 2 trial studies furmonertinib alone or with other treatment options to control advanced lung cancer that has specific EGFR gene changes. It may help by targeting the cancer-driving EGFR mutation, especially in people whose mutation is confirmed by a ctDNA blood test.
ChangchunAges 18 years+ - NCT05341583RecruitingPhase 3
Ensartinib after lung cancer surgery for ALK-positive patients
This Phase 3 trial tests whether ensartinib given after surgery can lower the risk of lung cancer coming back in people with ALK-positive non-small cell lung cancer. You may be eligible if your tumor was completely removed and your recovery and lab tests meet specific requirements.
TianjinAges 18 years+ - NCT05344209RecruitingPhase 2
Pembrolizumab plus or minus vaccine for advanced lung cancer
This Phase 2 trial studies pembrolizumab (an immune-boosting cancer medicine) alone or with an added investigational UV1 vaccine in people with advanced non-small cell lung cancer. It aims to see whether adding the vaccine improves safety and effectiveness, especially in tumors with high PD-L1 levels.
Drammen, AkershusAges 18 years+ - NCT05351788RecruitingPhase 2
Study drug combo for advanced lung cancer with specific gene results
This Phase 2 trial tests a combination treatment to control advanced or metastatic non-small cell lung cancer (NSCLC). It is mainly for people whose tumor has specific gene features (EGFR and ALK testing results) and who are able to provide tumor tissue for biomarker testing.
Guangzhou, GuangdongAges 18–75 - NCT05352035Recruiting
Study tumor evolution in early lung cancer after surgery
This study looks at how lung cancer changes over time by analyzing tumor tissue and blood. It may help researchers understand what drives cancer relapse after early-stage surgery.
BeijingAges 18 years+ - NCT05355701RecruitingPhase 1
Testing a new drug for advanced cancers with BRAF changes
This Phase 1 trial studies PF-07799933, a new medicine, in people whose advanced solid tumors have specific BRAF genetic changes. It may help if your cancer has continued to grow after standard treatments, and there may be specific options depending on your cancer type and past therapies.
Fayetteville, ArkansasAges 16 years+ - NCT05361174RecruitingPhase 1/Phase 2
Testing an IOV-4001 infusion for advanced melanoma or lung cancer
This trial studies how well and how safely an infusion called IOV-4001 works in adults with advanced melanoma or non-small-cell lung cancer that cannot be removed with surgery. It also aims to see what side effects occur and whether the treatment can help control the cancer.
Los Angeles, CaliforniaAges 18–70 - NCT05363280RecruitingPhase 2
Second-treatment study for lung or kidney cancer after initial therapy
This Phase 2 study tests a new treatment for people with small cell lung cancer, non-small cell lung cancer, or kidney cancer after they have finished their first main treatment. It may help shrink tumors or control the cancer further.
Birmingham, AlabamaAges 18 years+ - NCT05363319Recruiting
Cemiplimab study in adults with advanced lung cancer
This observational study looks at how well cemiplimab works and how safe it is for adults with advanced non-small cell lung cancer in everyday care in Europe. It mainly follows patients already prescribed cemiplimab, and asks them to complete questionnaires.
Klagenfurt, CarinthiaAges 18 years+
Hear when a new Lung Cancer, Small Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer, small cell?
- Yes. Clin2 currently lists 1,516 recruiting lung cancer, small cell studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer, small cell trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer, small cell trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.